Filing Details
- Accession Number:
- 0000899243-22-001525
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-10 20:35:56
- Reporting Period:
- 2022-01-06
- Accepted Time:
- 2022-01-10 20:35:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1658551 | Amylyx Pharmaceuticals Inc. | AMLX | Pharmaceutical Preparations (2834) | 464600503 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1829696 | Isaac Cheng | C/O Amylyx Pharmaceuticals, Inc. 43 Thorndike Street Cambridge MA 02142 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-01-06 | 1,409,035 | $0.00 | 1,409,035 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2022-01-06 | 6,410,964 | $0.00 | 7,819,999 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2022-01-06 | 974,107 | $0.00 | 8,794,106 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2022-01-06 | 1,621,544 | $0.00 | 10,415,650 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2022-01-06 | 6,578 | $19.00 | 6,578 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2022-01-06 | 1,409,035 | $0.00 | 1,409,035 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2022-01-06 | 6,410,964 | $0.00 | 6,410,964 | $0.00 |
| Common Stock | Series C-1 Preferred Stock | Disposition | 2022-01-06 | 974,107 | $0.00 | 974,107 | $0.00 |
| Common Stock | Series C-2 Preferred Stock | Disposition | 2022-01-06 | 1,621,544 | $0.00 | 1,621,544 | $0.00 |
| Common Stock | Stock Option (Right to Buy) | Acquisiton | 2022-01-06 | 8,400 | $0.00 | 8,400 | $19.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 8,400 | 2032-01-06 | No | 4 | A | Direct |
Footnotes
- Upon the closing of the Issuer's initial public offering, all shares of Series A , Series B, Series C-1 and Series C-2 Preferred Stock will convert into the number of shares of Common Stock of the Issuer and have no expiration date.
- These shares are held directly by Morningside Venture Investments Limited, or Morningside, and MVIL, LLC, a wholly-owned subsidiary of Morningside. The Reporting Person is an investment professional at Morningside Technology Advisory, LLC, an indirect advisor to Morningside and MVIL, LLC and may be deemed to indirectly beneficially own the shares held by Morningside and MVIL, LLC. The Reporting Person has no voting or dispositive power over the shares held by the Morningside shareholder entities and therefore disclaims beneficial ownership of such shares.
- This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Billionaire Hedge Funds
